Division of Radiation Oncology, Small Animal Department, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Department of Physics, University of Zurich, Zurich, Switzerland.
Vet Comp Oncol. 2020 Dec;18(4):626-633. doi: 10.1111/vco.12583. Epub 2020 Mar 22.
Treatment of epithelial sinonasal tumours in cats is not commonly reported. In the newer reports, palliative radiation protocols have been described more often than definitive-intent protocols. In this multi-institutional retrospective study, we included 27 cats treated with single-modality radiotherapy. Cats were irradiated using 10 daily fractions of 4.2 Gy. Three cats (11.1%) experienced a complete clinical response and 17 (63%) had a partial clinical response. Stable clinical disease was noted in three cats (11.1%). Four cats (14.8%) showed progression within 3 months following treatment. The median time to progression for all cases was 269 days (95 % confidence intervals [CI]: 225; 314). The proportion of cats free of progression at 1 and 2 years was 24% (95% CI: 22%; 26%) and 5% (95% CI: 5%; 6%), respectively. None of the prognostic factors evaluated were predictive of outcome (anaemia, tumour volume at the time of staging, modified Adams stage, intracranial involvement, facial deformity, epistaxis, inappetence or weight loss). Median overall survival (OS) for all deaths was 452 days (95% CI: 334; 571). The proportion of cats alive at 1 and 2 years was 57% (95% CI: 37%; 77%) and 27% (95% CI: 25%; 29%), respectively. Surprisingly, cats with epistaxis had a longer median OS of 828 days (95% CI: 356; 1301) compared to 296 days (95% CI: 85; 508) in cats without epistaxis, (P = .04, Breslow). Radiation therapy used as a single modality for the treatment of feline sinonasal carcinoma improved clinical signs and was well tolerated but progression within a year was common.
猫的上皮性鼻窦肿瘤的治疗并不常见。在最近的报告中，姑息性放疗方案比根治性意图方案更常被描述。在这项多机构回顾性研究中，我们纳入了 27 只接受单一模式放疗的猫。猫接受了 10 次每日 4.2Gy 的分次照射。3 只猫（11.1%）完全缓解，17 只猫（63%）部分缓解。3 只猫（11.1%）疾病稳定。4 只猫（14.8%）在治疗后 3 个月内出现进展。所有病例的中位进展时间为 269 天（95%置信区间[CI]：225；314）。1 年和 2 年无进展的猫比例分别为 24%（95%CI：22%；26%）和 5%（95%CI：5%；6%）。评估的预后因素均无预测作用（贫血、分期时的肿瘤体积、改良的 Adams 分期、颅内侵犯、面部畸形、鼻出血、食欲不振或体重减轻）。所有死亡的猫的中位总生存期（OS）为 452 天（95%CI：334；571）。1 年和 2 年存活的猫比例分别为 57%（95%CI：37%；77%）和 27%（95%CI：25%；29%）。令人惊讶的是，有鼻出血的猫中位 OS 为 828 天（95%CI：356；1301），而无鼻出血的猫为 296 天（95%CI：85；508），差异有统计学意义（P =.04，Breslow）。作为治疗猫鼻窦癌的单一模式，放射治疗改善了临床症状且耐受性良好，但在一年内进展很常见。
